降钙素基因相关肽在偏头痛中的作用及其靶向药物的研究进展  

Role of CGRP in Migraine and Research Advances in CGRP-Targeted Drugs

作　　者：李雪 戚微岩[1] 徐寒梅[1] 胡加亮[1] LI Xue;QI Weiyan;XU Hanmei;HU Jialiang(Jiangsu Provincial Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学江苏省合成多肽药物发现与评价工程研究中心,江苏南京211198

出　　处：《药学进展》2024年第2期151-160,共10页Progress in Pharmaceutical Sciences

摘　　要：偏头痛是一种常见的神经系统性疾病,是世界上最具致残性疾病之一。偏头痛损害身心健康,影响生活质量,给患者带来巨大的精神和经济负担。目前偏头痛治疗方案主要包括急性和预防性治疗。随着对偏头痛发作相关信号分子的探索,越来越多的治疗方法被开发用于偏头痛治疗,降钙素基因相关肽(CGRP)受体拮抗剂作为一种新兴偏头痛治疗方法备受关注。综述CGRP介导的偏头痛发病机制及最新药物研究进展,以期为偏头痛治疗相关药物的开发提供参考。Migraine is a common neurological disease and one of the most disabling diseases in the world.It brings enormous economic and social burdens to patients,impairs their physical and mental health,and affects their quality of life.Currently,the treatment options for migraines mainly include acute and preventive treatments.With the exploration of signal molecules related to migraines,more and more treatments have been developed.As a new emerging treatment for migraines,calcitonin gene-related peptide(CGRP)receptor antagonists have attracted much attention.This article reviews the pathogenesis of migraines mediated by CGRP and the research advances in CGRPtargeted drugs,aiming to provide some reference for the development of migraine drugs.

关 键 词：偏头痛 降钙素基因相关肽 受体拮抗剂 单克隆抗体 

分 类 号：R747.2[医药卫生—神经病学与精神病学]